The undercurrent of the pharmaceutical talent market is bringing about these changes

In recent years, with the normalization of centralized procurement in China and the advancement of medical insurance, many pharmaceutical companies have also faced corresponding challenges
.
Among them, many pharmaceutical companies have begun to actively adjust their business in order to meet the challenges
.
In this context, the flow of personnel in the pharmaceutical industry has also become more frequent
.
On March 28, Simcere announced the appointment of Danny Chen as the senior vice president of the group, responsible for promoting the company's translational science and neurological research and development work, as well as the establishment and management of the Beijing Innovation Center's research and development team to enhance Simcere's capabilities in the field of central nervous system therapy.
Global R&D capabilities
.
On March 22, ST Ink Pharmaceutical announced that the company's board of directors received the resignation report submitted by the secretary of the board of directors Luo Dingwei on March 18, 2022, and the resignation will take effect on March 18, 2022
.
Luo Dingwei continued to serve as the company (director and deputy general manager) after his resignation
.
On March 18, Darui Bio announced that Mr.
Li Hu, the company's director, will no longer serve as a director from March 17, 2022 due to personal reasons
.
The above-mentioned resigned personnel no longer hold other positions in the company after their resignation
.
On the same day, Mule Medical also announced that the board of directors of the company received the resignation report submitted by director Mr.
Zhu Ruibing on March 17, 2022, and he applied for his resignation due to personal work arrangements
.
After resigning, he will no longer hold other positions in the company
.
In mid-March, Zai Lab issued an announcement to appoint Josh Smiley as chief operating officer, and the official inauguration date is August 1, 2022
.
It is understood that Smiley previously served as Lilly's chief financial officer
.
In addition to the above-mentioned companies, according to incomplete statistics, in just over three months since 2022, more than 120 executives from nearly 100 pharmaceutical companies in China have left, many of whom are chairman, general manager, Deputy general manager, president, vice president, core technical personnel and other positions
.
It is worth noting that among the personnel changes of many pharmaceutical companies, it can also be clearly found that executives of multinational pharmaceutical companies are flowing to local pharmaceutical companies.

.
It is reported that in less than three months from the beginning of 2022, nearly 10 senior executives of multinational pharmaceutical companies have changed
.
Industry insiders said that the frequent resignation of senior executives of multinational pharmaceutical companies is mainly due to the fact that multinational pharmaceutical companies have been greatly affected by volume purchases and the intensive adjustment of business lines
.
However, while the executives of multinational pharmaceutical companies have moved to local companies, many executives have returned to multinational pharmaceutical companies in a short period of time.
For example, Qian Wei, general manager of the oncology field of Roche's customer interaction business model in China, left Roche last June.
Joined Junshi Bio, and returned to Roche after 6 months
.
Not long ago, it was reported that the whereabouts of Dr.
Huang Weijuan, a core technician who had just left BeiGene, was confirmed, and the cancer drug research and development company Prelude Therapeutics confirmed to appoint him as the company's Chief Medical Officer (CMO), starting in April 2022.
Effective on the 4th (US local time)
.
In addition, Bian Xin, President of Roche China, has also returned to Roche after working in BeiGene for one year after resigning from Xi'an Janssen.
.
.
In this regard, the industry believes that compared with other industries, the talent market for pharmaceutical companies is more Undercurrents are surging, full of uncertainty
.
Therefore, for local pharmaceutical companies, compared to hiring executives with high salaries, pharmaceutical companies need to re-examine the competition situation in the entire jungle, and return to the value of drugs themselves after shock adjustments
.
It is understood that, in fact, domestic pharmaceutical companies have been increasing their investment in innovative research and development.
The industry expects that the product pipeline of pharmaceutical companies will become more and more abundant in the future.
Give more and more companies more new opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.